Global Dry Needling Treatment Market
As the global economy mends, the 2021 growth of Dry Needling Treatment will have significant chan ... Read More
As the global economy mends, the 2021 growth of Non-corticosteroid Immunomodulator will have significant change from previous year. According to our (LP Information) latest study, the global Non-corticosteroid Immunomodulator market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Non-corticosteroid Immunomodulator market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Non-corticosteroid Immunomodulator market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Non-corticosteroid Immunomodulator market, reaching US$ million by the year 2028. As for the Europe Non-corticosteroid Immunomodulator landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Non-corticosteroid Immunomodulator players cover Accord Healthcare, Bristol-Myers Squibb Company, Astella Pharma, and Genzyme Co., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-corticosteroid Immunomodulator market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitors
IMDH Inhibitors
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Organ Transplantation
Atopic Dermatitis
Crohn’s Disease
Ulcerative Colitis
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Accord Healthcare
Bristol-Myers Squibb Company
Astella Pharma
Genzyme Co.
GlaxoSmithKline PLC
Merck KGaA
Glenmark Pharmaceuticals, Inc.
Pfizer Inc.
Mylan Laboratories Inc.
Actavis, Inc.
Novartis AG
Zydus Cadila
As the global economy mends, the 2021 growth of Dry Needling Treatment will have significant chan ... Read More
As the global economy mends, the 2021 growth of Fish Odor Syndrome Treatment will have significan ... Read More
As the global economy mends, the 2021 growth of Anti-Dermatomycosis Treatment will have significa ... Read More
As the global economy mends, the 2021 growth of Exploding Head Syndrome Treatment will have signi ... Read More